Jingdong Zhang

Jingdong Zhang

Auto-generated profile, based on publicly available information

Jingdong Zhang

Department of Medical Oncology, First Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
YZYe Zhang
Ye Zhang
JQJinglei Qu
Jinglei Qu
LXLing Xu
Ling Xu
KHKezuo Hou
Kezuo Hou
YLYunpeng Liu
Yunpeng Liu
β-Elemene, a compound found in an herb used in traditional Chinese medicine, has shown promising anti-cancer effects against a broad spectrum of tumors. The mechanism by which β-elemene kills cells remains unclear. The aim of the present study is to investigate the anti-tumor effect of β-elemene on human gastric cancer cells and the molecular mechanism involved.

Verified
Journal Article
Open access
PDF file
NSNa Song
Na Song
SLShizhou Liu
Shizhou Liu
JZJingdong Zhang
Jingdong Zhang
JLJing Liu
Jing Liu
LXLing Xu
Ling Xu
XQXiujuan Qu
Xiujuan Qu
Aberrant MET expression and hepatocyte growth factor (HGF) signaling are implicated in promoting resistance to targeted agents; however, the induced MET activation by epidermal growth factor receptor (EGFR) inhibitors mediating resistance to targeted therapy remains elusive. In this study, we identified that cetuximab-induced MET activation contributed to cetuximab resistance in Caco-2 colon cancer cells. MET inhibition or knockdown sensitized Caco-2 cells to cetuximab-mediated growth inhibition. Additionally, SRC activation promoted cetuximab resistance by interacting with MET. Pretreatment with SRC inhibitors abolished cetuximab-mediated MET activation and rendered Caco-2 cells sensitive to cetuximab. Notably, cetuximab induced MET/SRC/EGFR complex formation. MET inhibitor or SRC inhibitor suppressed phosphorylation of MET and SRC in the complex, and MET inhibitor singly led to disruption of complex formation. These results implicate alternative targeting of MET or SRC as rational strategies for reversing cetuximab resistance in colon cancer.


20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
XQXiujuan Qu
Xiujuan Qu
ZWZhenhai Wu
Zhenhai Wu
SWShuo Wang
Shuo Wang
JQJinglei Qu
Jinglei Qu
LZLingyun Zhang
Lingyun Zhang
YLYunpeng Liu
Yunpeng Liu
E15024 Background: This pilot study is aimed to evaluated the efficacy and safety of irinotecan plus raltitrexed as second-line treatment for advanced colorectal cancer patients. Methods: A pilot study was made among patients with advanced, previously treated colorectal cancer from June 2013 to April 2016 in the First Hospital, China Medical University,. A total of 13 patients eligible were enrolled to receive irinotecan at a dose of 180mg/m2 d1, plus raltitrexed at a dose of 3mg/m2 d1, every 3 weeks, until disease progression or un-tolerable adverse events. All statistical analyses were performed using the SPSS (21.0) software program. Kaplan–Meier analysis and Log-rank test were used for survival analysis. P < 0.05 was considered as statistically significant. The primary end point was time to progression (TTP) and objective response rate (ORR), the secondary end point was safety. Results:The median follow-up time was 10.1 months at data cut-off on Dec1, 2016. 11 patients were defined progression of disease (PD) based on the criteria of RECIST 1.1 and 6 patients died. The median TTP of second-line was 4.0 months. The rate of disease control rate (DCR) was 46.2% (6patients stable disease). In univariate analysis, sex (3.2months of 12male patients versus 4.6months of 1female patient, P = 0.926), body mass index (BMI) (3.2months of 5 patients BMI < = 24 versus 4.0months of 8 patients BMI > 24, P = 0.311), site of tumor (4.0months of left versus 3.2months of right, P = 0.555) were not associated with TTP. Safety was assessed within 10 patients including nausea (70%), vomiting (30%), diarrhea (60%), constipation (10%), fatigue (90%), fever (20%), hand foot syndrome (20%), rash (40%), alopecia (40%), palpitations (20%), oral mucositis (10%), neurotoxicity (50%). 2 of 9 patients (22.2%) had hematologic toxic. Liver injury occurred in 3 of 8 patients (37.5%) and no kidney injury was reported. Conclusions: In advanced colorectal cancer patients, irinotecan plus raltitrexed as second-line treatment showed encouraging clinical activity and a tolerable safety profile.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TWTi Wen
Ti Wen
XQXiujuan Qu
Xiujuan Qu
YLYi Li
Yi Li
YTYuee Teng
Yuee Teng
JZJingdong Zhang
Jingdong Zhang
YLYunpeng Liu
Yunpeng Liu
E15570 Background: Gastric cancer is a leading cause of cancer death worldwide, and its prognostic factors remain unclear. TNM staging was used to predict the prognosis of GC, however, it cannot meet current demands. To improve prediction efficiency, a model that reflects both tumor-related factor and host's local immune response in tumor microenvironment (TME) is needed. Immune checkpoint proteins regulate T-cell function to promote cancer immune escape. PDL1/PD-1 pathway, one of the immune checkpoint pathways, has become a new target in cancer treatment. Here, we aimed to illuminate the prognostic roles of immune checkpoint protein in GC. Methods: Immune checkpoint proteins expressed in tumor microenvironment (TME) were detected by IHC staining. Survival analysis was performed by the Kaplan-Meier method. A prognostic model was constructed from 174 gastric cancer patients using a scoring system, which was based on hazard ratios in a Cox proportional hazard model. Results: We examined PD-L1, PD-1, CD8 protein expression in TME from 174 GC patients (pts), and explored their effects on pt’s overall survival (OS). Our results showed that TC PD-L1+ was associated with better clinical outcomes, including longer OS et al (P < 0.05). However, PD-L1+ or PD-1+ IC was correlated with poorer OS (P = 0.0244, P = 0.024). Furthermore, multivariate analysis identified PD-L1+ TC, PD-L1+ IC, PD-1+ IC, CD8high IC, lauren classify, lymphatic invasion and AJCC stage were independent prognostic factors. A prognostic model was established by combination of these factors. Patients were categorized into low-/median-/high-risk groups according to their scores, and the 5-year survival rates were 96%, 56.23% and 18.36%, respectively (P < 0.0001). Our seven-factors prognostic model yielded an area under the ROC curve (AUC) of 0.855 for prediction of mortality at 5 years, which was superior to TNM stage with an AUC of 0.685. Conclusions: This study showed a prognostic model based on different prognostic roles of immune checkpoint proteins, which was more accuracy than TNM staging and might provide guidance for immunotherapy options in GC.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LXLing Xu
Ling Xu
XQXiujuan Qu
Xiujuan Qu
RMRui Ma
Rui Ma
YTYuee Teng
Yuee Teng
JZJingdong Zhang
Jingdong Zhang
YLYunpeng Liu
Yunpeng Liu
E23246 Background: PIK3CA mutation has been studied in various solid cancers. However, the impact of PI3KCA mutation on solid cancers is controversial. The aim of this study was to evaluate the clinicopathological and prognostic relevance of PIK3CA mutation in Chinese solid cancers patients. Methods: PIK3CA mutations were screened in various tumor specimens using next generation sequencing technology. Correlation between PIK3CA mutations and clinicopathological characteristics was analyzed by Spearman’s correlation. Overall survivals were analyzed by using the Kaplan–Meier method and compared by the log-rank test. Statistical data were obtained by using SPSS for Windows version 20.0. P values < 0.05 were considered to indicate statistically significant results. Results: In total, 13.69 % (36/263) of all patients harbored PIK3CA mutations. PIK3CA mutations were more commonly observed in ECOG PS 0 patients (P = 0.011). PIK3CA mutations were 19.05 % (4/21) in gastric cancer, 9.47 % (9/95) in colorectal cancer, 10.69 % (14 /131) in lung cancer, and 56.25 % (9/16) in breast cancer patients, respectively. PIK3CA mutations are common in ECOG PS 0 colorectal cancer patients (P = 0.005) and > = 60 years gastric cancer patients (P = 0.006). In PIK3CA mutations patients, exon 9 mutations (44.44%, 4/9) was higher in colorectal cancer, exon 13 mutations (64.29%, 9/14) was higher in lung cancer, and exon 20 mutations (44.44%, 4/9) was higher in breast cancer, P = 0.015. The overall survival of PIK3CA mutant-type patients was 26 (95% CI: 15.8-36.2) months, while PIK3CA wild-type patients was 15 (95% CI: 10.7-19.3) months. PIK3CA mutations were significantly associated with the longer survival time (P = 0.049). Conclusions: The patients with mutant PIK3CA had distinct characteristics in ECOG PS and have better survival in Chinese solid cancers.